This study looks at the long-term safety and effectiveness of a medicine called ibrutinib. It is for people with certain types of blood cancers, including chronic lymphocytic leukemia and lymphoma. The goal is to provide continued treatment for those who have benefited from ibrutinib in previous studies.
The trial's ID number is NCT01804686. This is a Phase 3 trial, which means it is looking at how well the treatment works and how safe it is. It is not a regulated device by the FDA, and around 700 participants are expected to join.
Who can join
Adults aged 18 and older can join if they are currently taking ibrutinib in another study or have been on it for at least 6 months. They must also agree to use effective birth control and have a negative pregnancy test. Some health conditions may prevent participation, but the trial team will confirm eligibility.
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Waldenstrom Macroglobulinemia, Chronic Graft Versus Host Disease
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will take ibrutinib, an oral medication, once a day. Everyone in the study will receive the same treatment, which is based on their previous dosing. There will be no random assignment to different groups.
Where
This trial is enrolling at 32 locations. Recruiting sites are listed first.
Avera Medical Group
Sioux Falls, South Dakota
Recruiting
St. Joseph Hospital Center for Cancer Prevention and Treatment
Elected to the National Academy of Medicine. Treats leukemia and myelodysplastic syndrome. The main doctor for adults with blood cancers, like leukemia, lymphoma, and myeloma. Recognized at state, national or international level.
Professor and transplant specialist, UC Davis. Treats leukemia, lymphoma and multiple myeloma. The main doctor for adults with blood cancers, like leukemia, lymphoma, and myeloma. Recognized at state, national or international level.